Successful ex vivo expansion of hematopoietic stem cells (HSCs) would greatly benefit the treatment of disease and the understanding of crucial questions of stem cell biology. Here we show, using microarray studies, that the HSC-supportive mouse fetal liver CD3 + cells specifically express the proteins angiopoietin-like 2 (Angptl2) and angiopoietin-like 3 (Angptl3). We observed a 24-or 30-fold net expansion of long-term HSCs by reconstitution analysis when we cultured highly enriched HSCs for 10 days in the presence of Angptl2 or Angptl3 together with saturating levels of other growth factors. The coiled-coil domain of Angptl2 was capable of stimulating expansion of HSCs. Furthermore, angiopoietin-like 5, angiopoietin-like 7 and microfibril-associated glycoprotein 4 also supported expansion of HSCs in culture.
HSCs, defined by their ability to self-renew and to differentiate into all blood cell types, form the basis of bone marrow transplantation for treatment of cancers and hematopoietic disorders 1 , and are also a promising cell target for gene therapies that can potentially treat a broad variety of human diseases 2 . Development of these important clinical applications of HSCs is greatly hampered by the lack of understanding of the extracellular and intracellular signals that govern their fates as well as by the difficulty in carrying out ex vivo expansion of these cells.
Numerous attempts have been made to increase the number of long-term HSCs in culture 3, 4 . The use of stromal cell lines or combinations of cytokines have resulted in considerable self-renewal of mouse HSCs assayed 4-6 weeks after transplant, and have led to as much as a sixfold increase in mouse long-term HSC activity in culture [5] [6] [7] [8] [9] . The introduction of exogenous transcription factors can expand HSCs more substantially [10] [11] [12] , though gene transduction of HSCs may be dangerous to individuals in clinical settings 2 .
Because fetal liver HSCs undergo marked expansion during embryonic development, we hypothesized that certain fetal liver Lineage-positive cells might produce protein(s) that support HSCs 13 , and we identified a cell population that supports HSC expansion ex vivo: CD3 + Ter119 -cells isolated from embryonic day 15 (E15) mouse livers 13 . Microarray expression analysis showed that, among other proteins, insulin-like growth factor (IGF)-2 is specifically expressed in E15 fetal liver CD3 + cells, but not in several cell types that do not support HSC expansion in culture 13 . We subsequently developed a simple culture system using low but saturating levels of stem cell factor (SCF), thrombopoietin (TPO), IGF-2 and fibroblast growth factor 1 (FGF-1) in serum-free medium. As measured by competitive repopulation analyses, there was a greater than eightfold increase in numbers of long-term repopulating HSCs (LT-HSCs) after 10 d of culture of highly enriched bone marrow HSCs 14 .
Here we further analyzed gene expression of E15 mouse liver CD3 + cells using Affymetrix U74Bv2 and U74Cv2 mouse microarrays, and identified the proteins angiopoietin-like 2 (Angptl2) and angiopoietin-like 3 (Angptl3) as well as several other members of the family of angiopoietin-like proteins as potent stimulators of ex vivo expansion of HSCs.
RESULTS

Fetal liver CD3 + cells specifically express Angptl2 and Angptl3
In our DNA microarray analysis we focused on identifying secreted or membrane proteins that are specifically expressed in E15 mouse liver CD3 + cells but not in two other cell populations, adult CD3 + cells and fetal liver Gr-1 + cells, which do not support maintenance or expansion of HSCs in culture (Supplementary Table 1 Supplementary Fig. 1 online) . These proteins are also expressed in adult bone marrow cells, including the side population (SP) CD45 + Sca-1 + highly enriched HSC population 17 (Supplementary Fig. 1 online) . We therefore hypothesized that these two proteins, not previously thought to be involved in HSC biology, might support expansion of HSCs.
Angptl2 and Angptl3 stimulate ex vivo expansion of HSCs
We constructed a plasmid containing the entire coding sequence for human Angptl2 with a Flag tag fused at the C terminus in the eukaryotic expression vector pcDNA3.1(-) (Flag-Angptl2). After transient transfection of 293T cells, the culture supernatant contained secreted Flag-Angptl2 migrating with the expected B60 kDa size (Fig. 1a) . We showed that the majority of freshly isolated LT-HSCs and all LT-HSCs cultured for 4 d bound this protein ( Supplementary  Fig. 2 online) .
A representative of two independent experiments (Fig. 1b) shows that Angptl2 is a stimulator of ex vivo expansion of LT-HSCs. In our study, Angptl2 was not purified but was contained in the conditioned medium of 293T cells transfected with a Flag-Angptl2 expression vector; conditioned medium from mock-transfected cells served as a negative control. When 20 adult bone marrow SP CD45 + Sca-1 + cells, a highly enriched HSC population 17 , were cultured for 5 d in serumfree medium supplemented with SCF, essentially all LT-HSC activity was lost, as measured by competitive reconstitution (Fig. 1b) . After culture in the same medium with SCF and 100 ng/ml Flag-Angptl2 for 5 d, LT-HSC activity substantially increased. Similarly, HSCs cultured for 10 d in the presence of 10 ng/ml SCF, 20 ng/ml TPO, 20 ng/ml IGF-2 and 10 ng/ml FGF-1 (STIF medium) together with Angptl2 achieved a considerable increase in LT-HSC activity compared to culture in the same STIF medium without Angptl2. Stem cells cultured in the presence of Angptl2 repopulated both lymphoid and myeloid lineages of the primary recipients at 9 months after transplant ( Fig. 1c) as well as in secondary transplanted mice ( Fig. 1d) , indicating a net expansion of LT-HSCs. At 9 months after transplants, all mice were healthy and no tumors were observed. Addition of 100 ng/ml Flag-Angptl2 also caused an increase in expansion of shortterm (ST)-HSC activity, measured at 3 weeks after transplant (Fig. 1b) . 
Notably, we showed previously that culturing highly enriched HSCs in this same serum-free STIF medium results in an eightfold increase in numbers of LT-HSCs 14 . Because we observed an additional increase in the extent of HSC expansion by adding Angptl2, we propose that Angptl2 is a growth factor for HSCs, whose effect is additive to other known HSC growth factors.
To isolate purified recombinant Angptl2, we collected conditioned medium from Flag-Angptl2-transfected 293T cells and purified the Flag-tagged protein by immunoaffinity chromatography using an immobilized monoclonal antibody specific for the Flag epitope. SDS-PAGE of the eluted fraction showed two major bands, one at the position expected for full-length Flag-Angptl2 (B60 kDa), and the other a smaller peptide of B36 kDa (Fig. 2a) . Full-length FlagAngptl2 expressed in mammalian cells had a higher molecular weight than Angptl2 expressed in bacteria, consistent with a previous result that Angptl2 expressed in mammalian cells is glycosylated 15 . Western blotting with a Flag-specific M2 antibody, which recognizes the C-terminal Flag epitope, stained both bands (Fig. 2b) , as did an Angptl2-specific monoclonal antibody (Fig. 2c) . Thus the Flag-Angptl2 protein underwent partial proteolysis during purification.
The limiting dilution competitive repopulation assay 13, 14 (Fig. 3 ) was used to show that culture of purified HSCs with Angptl2 or Angptl3 together with other growth factors resulted in a greater than 20-fold increase in numbers of LT-HSCs. The frequency of long-term repopulating cells (competitive repopulating unit, CRU) in freshly isolated bone marrow SP CD45 + Sca-1 + cells is 1 per 23 at 3 months after transplant (95% confidence interval for mean: 1/15-1/35, n ¼ 25; Fig. 3a ) or 1 per 39 at 6 months after transplant (95% confidence interval for mean: 1/24-1/63; Fig. 3a) . That is, as calculated from Poisson statistics, injection of on average 23 or 39 freshly isolated bone marrow SP CD45 + Sca-1 + cells was sufficient to repopulate 63% (¼ 1-1/e) of transplanted mice. After the cells were cultured for 10 d in serum-free conditioned STIF medium with Angptl2, the number of cells was too small to be counted reliably. But based on the number of cells initially added to the culture, the CRU of the cultured cells was 1/1.1 at 3 months after transplant ( Fig. 3b ; 95% confidence interval for mean: 1/0.5-1/2.3, n ¼ 30) or 1/1.6 at 6 months after transplant ( Fig.  3b ; 95% confidence interval for mean: 1/1.1-1/2.3). In other words, injection of the cultured progeny of only 1.1 or 1.6 freshly isolated bone marrow SP CD45 + Sca-1 + cells was sufficient to repopulate 63% of the mice. Thus, the data show that the number of LT-HSCs (6 months after transplant) increased 24-fold (¼ 39/1.6) after culture (Fig. 3b) .
We used the same strategy to measure the effect of purified Angptl3. The CRU of the cultured cells was 1/0.7 at 3 months after transplant ( Fig. 3c ; 95% confidence interval for mean: 1/0.3-1/1.7, n ¼ 24) or 1/1.3 at 6 months after transplant ( Fig. 3c ; 95% confidence interval for mean: 1/0.9-1/2.0), again relative to the number of cells initially added to the culture. Therefore culture of bone marrow SP CD45 + Sca-1 + cells in the presence of purified Angptl3 for 10 d resulted in a 30 (39/ 1.3)-fold increase in number of repopulating LT-HSCs (6 months after transplant). Increase in HSC activity caused by Angptl3, like that caused by Angptl2, was highly reproducible, as shown by two additional experiments in which we cultured 20 bone marrow SP CD45 + Sca-1 + cells for 10 d in serum-free conditioned STIF medium with 100 ng/ml Angptl3. There was a 30-and 52-fold increase in extent of engraftment, for each experiment respectively, at 4 months after transplant. Thus, our culture system consistently achieved considerable increases of the repopulation activities of HSCs. Our data showed that mammalian cell-specific post-translational modifications of Angptl2 facilitate its stimulation of ex vivo HSC expansion (Fig. 4) . Confirming an earlier result of our study (Fig. 1b) , addition of 100 ng/ml mammalian cell expressed Angptl2 significantly increased HSC activity after culture (Fig. 4) . In contrast, 100 ng/ml bacterially expressed Angptl2 was unable to stimulate expansion of HSCs (Fig. 4) . This suggests that some mammalian-specific modification, presumably glycosylation (Fig. 2a) , may contribute to the ability of Angptl2 to stimulate expansion of LT-HSCs.
The isolated coiled-coil domain but not the fibrinogen-like domain of Angptl2 also stimulated ex vivo expansion of HSCs (Fig. 4) .
Several Angptl family members stimulate expansion of HSCs
Angptl2 and Angptl3 belong to a family of angiopoietin-like proteins 18 . Several members of this family, like Angptl2 and Angptl3, are capable of stimulating HSC expansion in culture (Fig. 5) . We generated Flag-tagged Angptl4 (ref. 19 ) by transient transfection of 293T cells followed by immunoaffinity purification using an immobilized Flag-specific monoclonal antibody. In addition, we obtained purified Angptl3 (produced in sf21 cells using a baculovirus system), GST-fused Angptl5 (produced by a cell-free wheat germ in vitro transcription-translational system) 20 and Angptl7 (produced by a bacterial expression system) 21 (Fig. 5a) .
We cultured bone marrow SP Sca-1 + CD45 + cells for 5 d in serum-free unconditioned STIF medium, in the presence of 100 ng/ ml of Angptl3, Angptl4, Angptl5 or 1 mg/ml of Angptl7 (Fig. 5a) . Addition of Angptl3 to the culture stimulated expansion of both ST-HSCs and LT-HSCs (Fig. 5a) . We also observed a significant increase in both ST-and LT-HSC activities after culture with Angptl5, and also after culture with 1 mg/ml of bacterially expressed Angptl7. In contrast, 100 ng/ml Angptl4 did not effectively stimulate expansion of HSCs. 
T E C H N I C A L R E P O R T S NATURE MEDICINE
We also tested the effects of two proteins with sequence similarity to Angptls, microfibril-associated glycoprotein 4 (Mfap4) 22 and fibrinogen-like 1 (Fgl1) 23 . Both full-length proteins were Flag tagged and generated by transient transfection of 293T cells. They were secreted into the medium and detected by western blotting (Fig. 5b) . We applied B100 ng/ml of both Flag-Mfap4 and Flag-Fgl1 to HSCs directly in serum-free conditioned STIF medium (Fig. 5b) . Competitive reconstitution analysis showed that Mfap4 stimulated ex vivo expansion of bone marrow SP Sca-1 + CD45 + LT-HSCs after a 5-d culture, whereas Fgl1 did not (Fig. 5b) .
DISCUSSION
The angiopoietin family of growth factors is composed of four members that bind to the Tie-2 tyrosine kinase receptor and are important modulators of angiogenesis 18 . The Tie-2-Ang1 signaling pathway also has a crucial role in maintaining HSCs in a quiescent state in the bone marrow niche 24 . There are seven known members of the angiopoietin-like protein family that share limited sequence homology with angiopoietins 18 . Similar to angiopoietins, each Angptl protein contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. Unlike angiopoietins, they do not bind to Tie-2 or Tie-1 (ref. 18); their receptors and the signal transduction pathways that they activate are unknown. This suggests that Angptls may have different biological functions than angiopoietins.
Limited published studies show that Angptl3 and Angptl6 promote angiogenesis, whereas the roles of Angptl1 and Angptl4 in angiogenesis are the subject of controversy 18 . Angptl3, Angptl4 and Angptl6 are involved in the regulation of lipid metabolism 18 . In particular, Angptl6 is a hepatocyte-derived circulating factor that prevents obesity and the development of insulin resistance 25 . Overall, given the paucity of publications on Angptls, we presume that most of their physiological activities remain to be discovered.
The stimulation of ex vivo expansion of HSCs by Angptl2 most probably results from a direct effect of the protein on these cells. We showed that the majority of freshly isolated LT-HSCs and all LT-HSCs cultured for 4 d bound this hormone; thus the unknown receptor(s) of Angptl2 are different from Tie-2, the receptor for Ang1, which is not expressed on cultured HSCs 14 . Furthermore, our cultures contained only 20 highly enriched HSCs in 160 ml of medium. Because of this low cell density, it is unlikely that any accessory cell(s) in this population respond to Angptl2 by producing sufficient amounts of other growth factors to stimulate expansion of HSCs.
Previously, we developed a simple serum-free culture system for bone marrow HSCs using saturating levels of SCF, TPO, IGF-2 and FGF-1; during 10 d of culture of highly enriched HSCs, we observed an eightfold increase in the number of LT-HSCs 14 . SCF, IGF-2 and FGF-1 all activate receptor protein-tyrosine kinases 13, 26, 27 , whereas TPO signals through a member of the cytokine receptor superfamily that requires a Janus kinase to activate intracellular signal transduction pathways 28 . Here we showed that addition of any of several members of the Angptl family-specifically Angptl2, Angptl3, Angptl5 and Angptl7, as well as Mfap4-results in a further increase in HSC activities. This suggests that the Angptls activate signal transduction pathways that cannot be activated by SCF, TPO, IGF-2 or FGF-1; however, until we clone and characterize the receptors for these Angptl proteins, we will be unable to understand how these proteins act together with other growth factors to stimulate HSC expansion. Because at least Angptl2 and Angptl3 are produced by HSC-supportive mouse fetal liver CD3 + cells, we suggest that both Angptl2 and Angptl3 normally function in vivo to stimulate expansion of fetal liver, and perhaps also adult, HSCs.
Our identification of Angptls as growth factors for mouse HSCs suggests that they might also be useful for ex vivo expansion of human bone marrow or cord blood HSCs. If so, these factors may be useful in ex vivo expansion of these cells as part of an HSC transplantation or gene therapy protocol.
METHODS
Mice. We purchased C57 BL/6 CD45.2 and CD45.1 mice from the Jackson Laboratory or the US National Cancer Institute and maintained them at the animal facility of the Whitehead Institute for Biomedical Research. All animal experiments were performed with the approval of the Massachusetts Institute of Technology Committee on Animal Care.
Angiopoietin-like proteins. We produced Flag-human Angptl2, the coiled-coil domain of human Angptl2, Flag-tagged fibrinogen-like domain of human Angptl2, Flag-human Angptl4, Flag-human Fgl1 and Flag-human Mfap4 by transient transfection of 293T cells using Lipofectamine 2000 (Invitrogen). After transfection, we cultured cells overnight in Iscove Modified Dulbecco Medium with 10% FBS, and then washed them with IMDM before culturing them in serum-free StemSpan medium (StemCell Technology) for another 24 h. We harvested the conditioned medium and used it in experiments in Figures  1, 2 and 5b. We always used medium from mock-transfected cells as a negative control. We used serum-free conditioned medium-cultured mock-transfected 293T cells for 4 h before addition of purified Angptl2 or Angptl3 in the experiments in Figure 3 . To purify Flag-Angptl2 and Flag-Angptl4, we cultured the corresponding plasmid-transfected 293T cells in IMDM with 10% FBS for 48 h or 72 h and collected the conditioned medium for Flag-specific affinity purification.
Purified mouse Angptl3 (mAngptl3) expressed by sf21 cells using a baculovirus expression system was a gift from R&D Systems. We purchased GSThAngptl5, a fusion protein of GST and human Angptl5 (hAngptl5) and produced by a cell-free wheat germ in vitro transcription-translation system, from Abnova Corporation. Bacterially expressed hAngptl2 and hAngptl7 were gifts from R&D Systems.
Production and purification of tagged Angptl2 and Angptl4. We constructed a fusion of the cDNA encoding human Angptl2 (ref. 15 ) and a Flag peptide sequence (as Flag-hAngptl2) or with Pro100-Lys330 of human IgG1 Fc sequence followed by Flag (as human FC-Flag-human Angptls) at the C terminus. We inserted the DNA into the pcDNA3.1 (-) vector (Invitrogen) downstream of the cytomegalovirus (CMV) promoter. Flag-Angptl4 was similarly constructed. We transfected plasmids into 293T cells using Lipofectamine 2000 (Invitrogen) and collected serum-containing conditioned medium at 48 h and 72 h after transfection. We added 1 tablet/50 ml of the Complete Protease Inhibitor Cocktail (Roche), 5 mg/ml phenylmethylsulfonylfluoride and 100 mM NaCl, and applied the medium to a Flag-specific epitope immunoaffinity column (ANTI-FLAG M2 affinity Gel, Sigma), using 500 ml resin/500 ml conditioned medium. We subsequently washed the column 10 times with a total of 100 volumes of TBS (50 mM Tris, pH 7.4, 150 mM NaCl) and eluted the Flag-hAngptl2 or Flag-hAngptl4 with 0.1 mg/ml Flag peptide (DYKDDDDK) dissolved in TBS.
Cell culture. We plated 20 bone marrow SP Sca-1 + CD45 + cells isolated from 8-10-week-old C57BL/6 CD45.2 mice in one well of a U-bottom 96-well plate (3799; Corning) with 160 ml of StemSpan serum-free medium (StemCell Technologies) supplemented with 10 mg/ml heparin (Sigma), 10 ng/ml mouse SCF, 20 ng/ml mouse TPO, 20 ng/ml mouse IGF-2 (all from R&D Systems) and 10 ng/ml human FGF-1 (Invitrogen) 14 , with or without the indicated amounts of angiopoietin-like proteins. As indicated above, some of these proteins had been purified and others were added from the conditioned medium of transfected 293T cells. We always used medium from mock-transfected cells as a negative control. After 3-10 d of culture as indicated, we harvested the cells for competitive transplantation. We term the unconditioned serum-free medium supplemented with 10 mg/ml heparin, 10 ng/ml mouse SCF, 20 ng/ml mouse TPO, 20 ng/ml mouse IGF-2 and 10 ng/ml human FGF-1 as unconditioned STIF medium, and the conditioned medium collected from 293T cells which was then supplemented with the above cytokines as conditioned STIF medium. For the purpose of competitive transplantation, we pooled cells from at least six culture wells and mixed them with competitors before we transplanted the indicated numbers of cells into each mouse.
Competitive reconstitution analysis. We mixed the indicated numbers of CD45.2 donor cells with 1 Â 10 5 freshly isolated CD45.1 competitor bone marrow cells, and injected the mixture intravenously through the retro-orbital route into each member of a group of 6-9-week-old CD45.1 mice previously irradiated with a total dose of 10 Gy. For secondary transplantation, bone marrow of three primarily transplanted mice were pooled and 2 Â 10 6 were transplanted into secondary recipients. To measure reconstitution of transplanted mice, we collected peripheral blood at the indicated times after transplant and measured the presence of CD45.1 + and CD45.2 + cells in lymphoid and myeloid compartments as previously described 13, 14 . Briefly, we collected peripheral blood cells by retro-orbital bleeding, followed by lysis of red blood cells and staining with FITC-CD45.2-specific and PE-CD45.1-specific, or PE-Thy1.2-specific (for T-lymphoid lineage), PE-B220-specific (for B-lymphoid lineage), PE-Mac-1-specific, PE-Gr-1-specific (cells costaining with Mac-1-specific and Gr-1-specific antibodies were deemed the myeloid lineage), or PE-Ter119-specific (for erythroid lineage) monoclonal antibodies (BD Pharmingen). The 'percent repopulation' shown in all figures except Figure 1c ,d was based on the staining results of FITC-CD45.2-specific and PE-CD45.1-specific antibodies. In all cases, we performed FACS analysis of the above-listed lineages to confirm multilineage reconstitution. Calculation of CRUs in limiting dilution experiments was conducted using L-Calc software (StemCell Technologies) 14 .
Note: Supplementary information is available on the Nature Medicine website.
